VIVUS, Inc. (NASDAQ:VVUS) average recommendation is hold with average Target Price of $11.30. VIVUS, Inc. (NASDAQ:VVUS) stock opened at $6.98 in last trading session and closed at $6.98. The 52 week range of the stock is $6.97 – $15.62 and the day range was $6.97 – $7.00.
Arena Pharmaceuticals (NASDAQ:ARNA) CEO Jack Lief sold 100,000 shares of Arena Pharmaceuticals stock on the open market in a transaction dated Friday, January 17th. The stock was sold at an average price of $7.81, for a total transaction of $781,000.00. Following the sale, the chief executive officer now directly owns 583,704 shares of the company’s stock, valued at approximately $4,558,728. Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) stock advanced 0.84% and finished the last session at $6.02. The EPS of the stock remained -0.08. Company’s market capitalization is $1.32 billion.
Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) average Recommendation is Hold with average Target Price of $7.03. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) shares closed at $6.88 on last trade day, by losing -6.90%. Stock 52 week range is $2.15 – $23.00. Company’s market capitalization is $1.28 billion.
Gilead Sciences, Inc. (NASDAQ:GILD) stock is downgraded by research firm from outperform to neutral. Gilead Sciences, Inc. (NASDAQ:GILD) stock opened at $80.04 in last trading session, and closed at $80.03, trading in the range of $79.85 – $80.15. The stock showed a positive/negative weekly performance of 0.58%.